The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

The biotech is using AI and a trove of health data to better understand why certain conditions progress and intervene ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

One attorney said the ruling “isn’t quite the stake in the heart.” The FDA is unlikely to challenge the court’s decision, but ...

The leaked budget draft, if approved by Congress, would reduce the FDA’s budget authority, indicating more disruption could ...

The startup, Veraxa, has $253 million in cash and is raising a crossover funding round to support a pipeline of T cell ...

The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...